# Invesco NASDAQ Biotech UCITS ETF (SBIX) **Page:** https://fundology.uk/fund/sbix · ISIN IE00BQ70R696 ## At a glance > Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise. As of 13/11/2026, SBIX (Invesco NASDAQ Biotech UCITS ETF, ISIN IE00BQ70R696) closed at £56.52 on the London Stock Exchange. Its ongoing charge is 0.40% a year (about £40 on £10,000). Over the five years to 13/11/2026 its total return was +57.3%, or +22.8% after UK CPIH inflation. ## Summary Invesco NASDAQ Biotech UCITS ETF is an exchange-traded fund (ETF) from Invesco, launched in 2014. It tracks the NASDAQ / Biotechnology. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.4% a year — about £40 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you. Latest close: **£56.52** (13/11/2026). ## Key facts | Fact | Value | |---|---| | Ticker (LSE) | SBIX | | ISIN | IE00BQ70R696 | | Also listed as | SBIO (London Stock Exchange, US dollars), NBTK (Xetra, euros) | | Category | Healthcare | | Type | ETF | | Provider | Invesco | | Tracks | NASDAQ / Biotechnology | | Income | Accumulating | | Ongoing charge | 0.40% a year (£40 per £10,000) | | Fund size | £503m | | Launched | 2014 | | Domicile | Ireland | | UK reporting fund status | Yes — on HMRC’s list of reporting funds (list of 02/11/2026); reporting fund since 04/11/2014 | ## Past returns (periods to 13/11/2026) After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after UK CPIH inflation. | Window | Return | After CPIH inflation | Measured as | |---|---|---|---| | 1 year | +33.28% | +28.56% | income reinvested | | 3 years | +86.52% | +68.51% | income reinvested | | 5 years | +57.26% | +22.75% | income reinvested | Returns: as reported (delayed data). Inflation: UK CPIH, latest month published. ## Calendar-year returns Calendar-year returns of Invesco NASDAQ Biotech UCITS ETF in pounds (price, with income reinvested in the fund): 2026 to 13/11/2026 +28.8%. Returns of Invesco NASDAQ Biotech UCITS ETF in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +43.7%. | Year | Return | After CPIH inflation | Measured as | |---|---|---|---| | 2026 to 13/11/2026 | +28.8% | +24.7% | Price | ## Risk metrics | Window | Volatility | Max drawdown | |---|---|---| | 1 year | 18.99% | -5.95% | ## Largest fall Volatility of Invesco NASDAQ Biotech UCITS ETF in pounds, annualised from weekly returns to 13/11/2026: 19.0% over 1 year. Largest fall in the price of Invesco NASDAQ Biotech UCITS ETF since August 2025, in pounds: −5.9% from 03/07/2026 to 31/07/2026. On 13/11/2026 the price of Invesco NASDAQ Biotech UCITS ETF was 0.9% below its highest weekly close since August 2025 (30/10/2026), in pounds. ## Charges compared with similar funds Ongoing charge of Invesco NASDAQ Biotech UCITS ETF 0.40% a year. Compared on 14/11/2026, 7 of the 28 other healthcare funds charge more, 2 the same and 19 less (share classes counted once). ## Funds tracking the same index 3 funds track NASDAQ / Biotechnology, this one included and share classes counted once; their ongoing charges range from 0.35% to 0.40% a year (13/11/2026). | Fund | Ongoing charge | 1 year | 3 years | 5 years | |---|---|---|---|---| | Invesco NASDAQ Biotech UCITS ETF (this fund) | 0.40% | +33.3% | +86.5% | +57.3% | | iShares NASDAQ US Biotechnology UCITS ETF | 0.35% | +33.2% | +86.4% | +57.1% | | iShares NASDAQ US Biotechnology UCITS ETF Dist | 0.35% | +34.0% | +86.5% | +57.5% | Returns are as reported, in pounds, income reinvested unless marked "(price)". ## Charges & eligibility - Ongoing charges figure (OCF): **0.40%** per year (as of 13/11/2026) - Stocks and shares ISA eligible: usually (check with your platform) - SIPP eligible: usually (check with your provider) - ISA and SIPP mean the kind of product usually qualifies under HMRC rules. We do not check each platform’s list — each provider decides which funds it offers. Crypto ETNs have not qualified for a stocks and shares ISA since 06/04/2026, and overseas funds that are not UK-recognised UCITS, such as Swiss ETFs, do not usually qualify. ## What it holds As of 12/11/2026, SBIX holds 244 positions, according to its published holdings. The largest is Gilead Sciences at 9.03% of the fund; the ten largest make up 48.2%. ### Top holdings Largest positions (as of 12/11/2026), as a percentage of the whole fund: | # | Holding | Ticker | Weight | |---|---|---|---| | 1 | Gilead Sciences | [GILD](https://fundology.uk/stock/GILD) | 9.03% | | 2 | Amgen | [AMGN](https://fundology.uk/stock/AMGN) | 8.55% | | 3 | Vertex Pharmaceuticals | [VRTX](https://fundology.uk/stock/VRTX) | 7.84% | | 4 | Regeneron Pharmaceuticals | [REGN](https://fundology.uk/stock/REGN) | 6.19% | | 5 | Moderna | [MRNA](https://fundology.uk/stock/MRNA) | 5.95% | | 6 | Revolution Medicines | [RVMD](https://fundology.uk/stock/RVMD) | 2.43% | | 7 | Biogen | [BIIB](https://fundology.uk/stock/BIIB) | 2.38% | | 8 | Illumina | [ILMN](https://fundology.uk/stock/ILMN) | 2.04% | | 9 | Royalty Pharma · Class A | [RPRX](https://fundology.uk/stock/RPRX) | 1.97% | | 10 | Roivant Sciences | [ROIV](https://fundology.uk/stock/ROIV) | 1.86% | ## Where it invests Shares of the whole fund. Bonds, cash and positions without a classification are shown as they come, not guessed. ### By country As published for the fund, as of 12/11/2026. | Country | Weight | |---|---| | United States | 93.9% | | Belgium | 1.8% | | Denmark | 1.4% | | Canada | 0.6% | | Germany | 0.6% | | Netherlands | 0.4% | | France | 0.3% | | Switzerland | 0.3% | | Other countries | 0.7% | The 239 holdings on record (of 244 reported): https://fundology.uk/fund/sbix/holdings ## Questions people ask **What is the ongoing charge of SBIX?** The ongoing charge of SBIX is 0.40% a year — about £40 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of Invesco NASDAQ Biotech UCITS ETF 0.40% a year. Compared on 14/11/2026, 7 of the 28 other healthcare funds charge more, 2 the same and 19 less (share classes counted once). **What does SBIX track?** SBIX tracks the NASDAQ / Biotechnology. **Is SBIX accumulating or distributing?** SBIX is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you. **What is the ISIN of SBIX?** The ISIN of SBIX is IE00BQ70R696. An ISIN identifies one exact share class of a fund; SBIX is its ticker on the London Stock Exchange. The same share class is also listed as SBIO (London Stock Exchange, US dollars) and NBTK (Xetra, euros). **What does SBIX hold?** As of 12/11/2026, SBIX holds 244 positions, according to its published holdings. The largest is Gilead Sciences at 9.03% of the fund; the ten largest make up 48.2%. Its ten largest holdings are Gilead Sciences (9.03%), Amgen (8.55%), Vertex Pharmaceuticals (7.84%), Regeneron Pharmaceuticals (6.19%), Moderna (5.95%), Revolution Medicines (2.43%), Biogen (2.38%), Illumina (2.04%), Royalty Pharma · Class A (1.97%) and Roivant Sciences (1.86%). **What were SBIX’s returns in each of the last five years?** Calendar-year returns of SBIX in pounds (price, with income reinvested in the fund): 2026 to 13/11/2026 +28.8%. Past performance is not a guide to future returns. **How has SBIX done after inflation?** Over the five years to 13/11/2026 SBIX’s total return was +57.3%, or +22.8% after UK CPIH inflation. Past performance is not a guide to future returns. --- We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments. Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.